Reduction in mortality from breast cancer - Screening and increased use of adjuvants are responsible - adjuvants more so

被引：16

作者：

Jones, AL ^{[1
]}

机构：

[1] UCL Royal Free & Univ Coll Hosp, Acad Dept Oncol, London NW3 2QG, England

来源：

BRITISH MEDICAL JOURNAL | 2005年 / 330卷 / 7485期

关键词：

D O I：

10.1136/bmj.330.7485.205

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：205 / 206

页数：2

共 12 条

[1]

Abe O, 1998, LANCET, V352, P930

[2] Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality [J].

Blanks, RG ;

Moss, SM ;

McGahan, CE ;

Quinn, MJ ;

Babb, PJ .

BRITISH MEDICAL JOURNAL, 2000, 321 (7262) :665-669

[3] 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study [J].

Bonadonna, G ;

Moliterni, A ;

Zambetti, M ;

Daidone, MG ;

Pilotti, S ;

Gianni, L ;

Valagussa, P .

BRITISH MEDICAL JOURNAL, 2005, 330 (7485) :217-220

[4] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J].

Coombes, RC ;

Hall, E ;

Gibson, LJ ;

Paridaens, R ;

Jassem, J ;

Delozier, T ;

Jones, SE ;

Alvarez, I ;

Bertelli, G ;

Ortmann, O ;

Coates, AS ;

Bajetta, E ;

Dodwell, D ;

Coleman, RE ;

Fallowfield, LJ ;

Mickiewicz, E ;

Andersen, J ;

Lonning, PE ;

Cocconi, G ;

Stewart, A ;

Stuart, N ;

Snowdon, CF ;

Carpentieri, M ;

Massimini, G ;

Bliss, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1081-1092

[5] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J].

Goss, PE ;

Ingle, JN ;

Martino, S ;

Robert, NJ ;

Muss, HB ;

Piccart, MJ ;

Castiglione, M ;

Tu, D ;

Shepherd, LE ;

Pritchard, KI ;

Livingston, RB ;

Davidson, NE ;

Norton, L ;

Perez, EA ;

Abrams, JS ;

Therasse, P ;

Palmer, MJ ;

Pater, JL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1793-1802

[6] Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer [J].

Hébert-Croteau, N ;

Brisson, J ;

Latreille, J ;

Rivard, M ;

Abdelaziz, N ;

Martin, G .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) :3685-3693

[7] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer [J].

Howell, A ;

Cuzick, J ;

Baum, M ;

Buzdar, A ;

Dowsett, M ;

Forbes, JF ;

Hoctin-Boes, G ;

Houghton, I ;

Locker, GY ;

Tobias, JS .

LANCET, 2005, 365 (9453) :60-62

[8] Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study [J].

Olsen, AH ;

Njor, SH ;

Vejborg, I ;

Schwartz, W ;

Dalgaard, P ;

Jensen, MB ;

Tange, UB ;

Blichert-Toft, M ;

Rank, F ;

Mouridsen, H ;

Lynge, E .

BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7485) :220-222A

[9]

Sainsbury R, 1999, LANCET, V353, P1132

[10] Breast carcinoma survival in Europe and the United States -: A population-based study [J].

Sant, M ;

Allemani, C ;

Berrino, F ;

Coleman, MP ;

Aareleid, T ;

Chaplain, G ;

Coebergh, JW ;

Colonna, M ;

Crosignani, P ;

Danzon, A ;

Federico, M ;

Gafà, L ;

Grosclaude, P ;

Hédelin, G ;

Macè-Lesech, J ;

Garcia, CM ;

Moller, H ;

Paci, E ;

Raverdy, N ;

Tretarre, B ;

Williams, EMI .

CANCER, 2004, 100 (04) :715-722

← 1 2 →